Scarica l'app Stockscreener
6.28
2.64%
-0.17
Dopo l'orario di chiusura:
6.28
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AURA Giù?
Forum
Previsione
Aura Biosciences Inc Borsa (AURA) Ultime notizie
Aura Biosciences (AURA) director awarded 15,000 RSUs and 30,000 options - Stock Titan
Aura Biosciences (NASDAQ: AURA) director receives RSUs and 30,000 stock options - Stock Titan
Aura Biosciences (AURA) director receives RSUs and stock options - Stock Titan
Aura Biosciences (AURA) awards director RSUs and $6.21 stock options - Stock Titan
Technical Reactions to AURA Trends in Macro Strategies - Stock Traders Daily
Aura Biosciences (AURA) Gains 3% as Shares Bounce from SupportNHNL Ratio - newsline.com
Aura Biosciences, Inc. 8-K Filing Details for June 11, 2026: Emerging Growth Status and Shareholder Vote Submission 1821 – Minichart - Minichart
InvestingPro’s Fair Value spotted Aura Biosciences’ 47% decline By Investing.com - Investing.com
Aura Biosciences Announces Results of 2026 Annual Meeting - TipRanks
Shareholders back Aura Biosciences (NASDAQ: AURA) directors and auditor - Stock Titan
Aura Biosciences Inc. Q1 2026 Earnings: Wider-than-Expected Loss Marks Early-Stage Pipeline Progress - newsline.com
Aura Biosciences gears up for Bel-Sar filing as pivotal eye cancer trial advances - MSN
Trading the Move, Not the Narrative: (AURA) Edition - Stock Traders Daily
Aura Biosciences highlights Bel-Sar eye cancer strategy, mid-year bladder data - MSN
Aura Biosciences completes phase 3 enrollment for eye cancer drug By Investing.com - Investing.com India
AURA Technical Analysis & Stock Price Forecast - Intellectia AI
Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma - The Manila Times
Aura Biosciences completes enrollment in Phase 3 trial for early choroidal melanoma treatment - Pluang
Aura Biosciences completes phase 3 enrollment for eye cancer drug - Investing.com
Eye cancer trial hits 108 patients as Aura tests new frontline therapy - Stock Titan
AURA Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Advances PipelinePost-Announcement Reaction - The Legal Advocate
AURA News | AURA BIOSCIENCES INC (NASDAQ:AURA) - ChartMill
Aura Biosciences Gears Up for Bel-Sar Filing as Pivotal Eye Cancer Trial Advances - TradingView
AURA: Bel-sar leads innovation in ocular oncology with robust data and a strong financial runway - TradingView
H.C. Wainwright Maintains Aura Biosciences(AURA.US) With Buy Rating, Maintains Target Price $24 - Moomoo
Ken Fisher's Aura Biosciences Inc(AURA) Holding History - GuruFocus
(AURA) Volatility Zones as Tactical Triggers - Stock Traders Daily
AURA Q1 2026 Earnings: EPS Misses Estimates, Stock Rises 2.4% on Pre-Clinical ProgressBalance Sheet Strength - Newser
Global Business Travel Group posts upbeat Q1 results, joins Cabaletta Bio, Aura Biosciences and other big stocks moving higher on Monday - MSN
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
AURA Director Holles Acquires 2.17M Stock Options on May 20, 2026 - Meyka
Aura Biosciences Highlights Bel-Sar Eye Cancer Strategy, Mid-Year Bladder Data - inkl
Aura Biosciences grants inducement equity awards to new CEO Natalie Holles under Nasdaq rules. - Pluang
Aura Biosciences Grants Inducement Equity Awards to New CEO Natalie Holles - Quiver Quantitative
Large equity awards granted to Aura Biosciences (AURA) director Natalie Holles - Stock Titan
New Aura Biosciences CEO awarded options on 2.17M shares at $7.39 - Stock Titan
AURA: Bel-sar shows promise for vision-preserving cancer therapy, with pivotal data expected soon - TradingView
Wall Street analysts predict a 201.49% upside in Aura Biosciences (AURA): Here's what you should know - MSN
LifeSci Capital Maintains Aura Biosciences(AURA.US) With Buy Rating, Maintains Target Price $23 - Moomoo
TradingKey - TradingKey
AURA Stock Price and Chart — NASDAQ:AURA - TradingView
Chen Yu and TCG Crossover report combined 9.9% stake in Aura Biosciences (AURA) - Stock Titan
Aura Biosciences to Participate in Upcoming Investor Conferences - The Manila Times
Leerink Partners Maintains Aura Biosciences(AURA.US) With Buy Rating, Cuts Target Price to $17 - Moomoo
Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights - The Manila Times
Major Investor Makes Dramatic Exit from Aura Biosciences - TipRanks
Aura Biosciences reports Q1 results, appoints new CEO - TipRanks
Aura Biosciences (NASDAQ: AURA) posts higher Q1 loss but extends cash runway - Stock Titan
Matrix Capital fund exits 6.9M Aura Biosciences (AURA) shares in open-market sale - Stock Titan
Matrix Capital exits Aura Biosciences (AURA) after 6.9M-share, $5.64 repurchase - Stock Titan
Aura Biosciences Q1 net loss widens on higher R&D costs - TradingView
Aura Biosciences 1Q Loss/Shr 50c >AURA - Moomoo
Aura Biosciences (NASDAQ: AURA) details $299M raise, cash runway and Phase 3 plans - Stock Titan
1.27%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):